Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.64 (market cap $29.60B), while iShares 7-10 Year Treasury Bond ETF trades at $92.96. Which is the better fit depends on your goals.
| ALNY | IEF | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | — |
52-Week High | $491.22 | $97.99 |
52-Week Low | $205.48 | $92.76 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
IEF trades at $93.075 with a modest 0.34% daily gain, though technical indicators show a bearish trend with moving averages signaling sell pressure. The ETF maintains consistent dividend distributions, with recent payouts of $0.31-$0.32 per share. Market sentiment is influenced by Treasury yield fluctuations and institutional positioning, with Bank of America increasing its stake by 69.8% in Q2 2026.
The outlook remains cautious as rising Treasury yields and inflation concerns pressure bond ETFs. Institutional accumulation provides support, but technical weakness and macroeconomic headwinds suggest limited near-term upside. Key risks include Fed rate policy uncertainty and oil price volatility affecting inflation expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
